Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01123785 · ClinicalTrials.gov registry record · Phase 1
A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
A Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Inotek Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 144
- Enrollment target
- 1
- Study location
NCT01123785: Completed Phase 1 study of Glaucoma and Ocular Hypertension, sponsored by Inotek Pharmaceuticals Corporation.
NCT01123785 is a Phase 1 study of Glaucoma and Ocular Hypertension that has completed, run by Inotek Pharmaceuticals Corporation. The registered enrollment target is 144 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01123785, a Phase 1 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Inotek Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 144 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG INO-8875
Study Locations (1)
California
- Lugene Eye Institute - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
What the finished NCT01123785 record still lists
NCT01123785 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (84% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01123785 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01123785 about?
NCT01123785 is a clinical study titled "A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma". The purpose of this study is to evaluate how tolerable, safe, and effective it is to give INO-8875 eye drops to adults with glaucoma or ocular hypertension.
What is the current status of trial NCT01123785?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 144 participants. The study started on 2010-05. Estimated completion is 2012-01.
What conditions does trial NCT01123785 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT01123785?
The interventions under investigation include: Placebo (DRUG), INO-8875 (DRUG).
Who is sponsoring clinical trial NCT01123785?
This trial is sponsored by Inotek Pharmaceuticals Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01123785 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01123785's enrollment target sits among peer trials
144 35th of 92 higher than 58 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Insulin for Glaucoma
RECRUITING · Phase 1
-
Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
ACTIVE NOT RECRUITING · Phase 1
-
Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution
ACTIVE NOT RECRUITING · Phase 1
-
Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt
COMPLETED · Phase 1
-
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
COMPLETED · Phase 1
-
Efficacy, Tolerability and Safety of RKI983 (0.05% & 0.10%) vs Xalatan in Patients With POAG or Ocular Hypertension
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia